StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Oncotelic Therapeutics's operating cash flow for the twelve months ending Jun 30, 2025 was -$540.19K. For fiscal 2025 it was -$1.38M. The highest annual figure on record is -$240.98K in fiscal 2018.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.38M–
FY2024Dec 31, 2024-$740.28K–
FY2023Dec 31, 2023-$1.32M–
FY2022Dec 31, 2022-$1.45M–
FY2021Dec 31, 2021-$4.43M–
FY2020Dec 31, 2020-$2.81M–
FY2019Dec 31, 2019-$2.28M–
FY2018Dec 31, 2018-$240.98K–
FY2017Dec 31, 2017-$10.93M–
FY2016Dec 31, 2016-$15.24M–
FY2015Dec 31, 2015-$11.93M–
FY2014Dec 31, 2014-$12.15M–
FY2013Dec 31, 2013-$7.00M–
FY2012Dec 31, 2012-$8.34M–
FY2011Dec 31, 2011-$11.78M–
FY2010Dec 31, 2010-$20.43M–
FY2009Dec 31, 2009-$28.67M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$92.20K–
Q1 FY2026Mar 31, 2026-$342.24K–
Q2 FY2025Jun 30, 2025-$126.15K–
Q1 FY2025Mar 31, 2025-$166.96K–
Q4 FY2024Dec 31, 2024-$103.89K–
Q3 FY2024Sep 30, 2024-$143.20K–
Q2 FY2024Jun 30, 2024-$261.77K–
Q1 FY2024Mar 31, 2024-$231.42K–
Q4 FY2023Dec 31, 2023-$372.62K–
Q3 FY2023Sep 30, 2023-$248.85K–
Q2 FY2023Jun 30, 2023-$448.56K–
Q1 FY2023Mar 31, 2023-$251.02K–
Q4 FY2022Dec 31, 2022-$80.68K–
Q3 FY2022Sep 30, 2022-$206.08K–
Q2 FY2022Jun 30, 2022-$203.13K–
Q1 FY2022Mar 31, 2022-$962.67K–
Q4 FY2021Dec 31, 2021-$1.07M–
Q3 FY2021Sep 30, 2021-$900.69K–
Q2 FY2021Jun 30, 2021-$1.21M-633.9%
Q1 FY2021Mar 31, 2021-$1.25M-4076.4%
Q4 FY2020Dec 31, 2020-$1.49M–
Q3 FY2020Sep 30, 2020-$1.58M–
Q2 FY2020Jun 30, 2020$227.47K–
Q1 FY2020Mar 31, 2020$31.47K–
Q4 FY2019Dec 31, 2019-$944.40K–
Q3 FY2019Sep 30, 2019-$443.07K–
Q2 FY2019Jun 30, 2019-$775.23K-188.9%
Q1 FY2019Mar 31, 2019-$118.00K–
Q4 FY2018Dec 31, 2018-$40.05K–
Q3 FY2018Sep 30, 2018-$191.03K–
Q2 FY2018Jun 30, 2018$872.10K–
Q1 FY2018Mar 31, 2018-$882.00K–
Q4 FY2017Dec 31, 2017-$793.00K–
Q3 FY2017Sep 30, 2017-$3.10M–
Q2 FY2017Jun 30, 2017-$3.34M–
Q1 FY2017Mar 31, 2017-$3.70M–
Q4 FY2016Dec 31, 2016-$4.23M–
Q3 FY2016Sep 30, 2016-$3.06M–
Q2 FY2016Jun 30, 2016-$3.55M–

More Oncotelic Therapeutics figures

See a number that looks wrong?